PI: Khaled Moussawi, M.D., Ph.D.
The goals of the Translational Neuropsychiatry Through Neuromodulation (TN²) Lab are to:
♦ Advance our understanding and treatment of substance use and neuropsychiatric disorders,
. ♦ Adhere to principles of scientific rigor and scientific excellence,
♦ Provide individualized mentorship plans to meet the individual members’ career goals, and
♦ Offer a safe and friendly environment that fosters teamwork and allows every member to grow and fulfill their potential
T he TN² lab investigates the neurobiology of substance use disorders and the use of neuromodulation techniques such as transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), and transcranial focused ultrasound (tFUS) in the treatment of substance use and other neuropsychiatric disorders. The lab focuses on relapse vulnerability, which persists for prolonged periods after abstinence from drug use. Of particular interest is cue reactivity, a major predictor and driver of relapse to drug seeking. The lab also uses neuromodulation to translate pre-clinical neurobiological findings into actionable clinical treatment protocols. As many symptoms of neurologic and psychiatric disorders are a manifestation of circuit dysfunction in the brain, neuromodulation with tools like TMS, DBS and tFUS has the potential to modify connectivity and plasticity in the underlying circuits, thereby treating the pathological processes in these circuits. Research in the TN² lab spans the spectrum from the bench to the bedside and involves translational pre-clinical as well as clinical research projects.